Literature DB >> 23201698

Lower-dose prescribing: minimizing "side effects" of pharmaceuticals on society and the environment.

Christian G Daughton1, Ilene Sue Ruhoy.   

Abstract

The prescribed use of pharmaceuticals can result in unintended, unwelcomed, and potentially adverse consequences for the environment and for those not initially targeted for treatment. Medication usage frequently results in the collateral introduction to the environment (via excretion and bathing) of active pharmaceutical ingredients (APIs), bioactive metabolites, and reversible conjugates. Imprudent prescribing and non-compliant patient behavior drive the accumulation of unused medications, which pose major public health risks from diversion as well as risks for the environment from unsound disposal, such as flushing to sewers. The prescriber has the unique wherewithal to reduce each of these risks by modifying various aspects of the practice of prescribing. By incorporating consideration of the potential for adverse environmental impacts into the practice of prescribing, patient care also could possibly be improved and public health better protected. Although excretion of an API is governed by its characteristic pharmacokinetics, this variable can be somewhat controlled by the prescriber in selecting APIs possessing environment-friendly excretion profiles and in selecting the lowest effective dose. This paper presents the first critical examination of the multi-faceted role of drug dose in reducing the ambient levels of APIs in the environment and in reducing the incidence of drug wastage, which ultimately necessitates disposal of leftovers. Historically, drug dose has been actively excluded from consideration in risk mitigation strategies for reducing ambient API levels in the environment. Personalized adjustment of drug dose also holds the potential for enhancing therapeutic outcomes while simultaneously reducing the incidence of adverse drug events and in lowering patient healthcare costs. Optimizing drug dose is a major factor in improving the sustainability of health care. The prescriber needs to be cognizant that the "patient" encompasses the environment and other "bystanders," and that prescribed treatments can have unanticipated, collateral impacts that reach far beyond the healthcare setting. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201698     DOI: 10.1016/j.scitotenv.2012.10.092

Source DB:  PubMed          Journal:  Sci Total Environ        ISSN: 0048-9697            Impact factor:   7.963


  17 in total

1.  Do pharmaceuticals reach and affect the aquatic ecosystems in Brazil? A critical review of current studies in a developing country.

Authors:  Gabrielle Rabelo Quadra; Helena Oliveira de Souza; Rafaela Dos Santos Costa; Marcos Antonio Dos Santos Fernandez
Journal:  Environ Sci Pollut Res Int       Date:  2016-10-13       Impact factor: 4.223

Review 2.  Potential Upstream Strategies for the Mitigation of Pharmaceuticals in the Aquatic Environment: a Brief Review.

Authors:  Benjamin D Blair
Journal:  Curr Environ Health Rep       Date:  2016-06

3.  Pharmacopollution and Household Waste Medicine (HWM): how reverse logistics is environmentally important to Brazil.

Authors:  André Luiz Pereira; Raphael Tobias de Vasconcelos Barros; Sandra Rosa Pereira
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-19       Impact factor: 4.223

4.  Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.

Authors:  Cierra N Sharp; Mark W Linder; Roland Valdes
Journal:  Crit Rev Clin Lab Sci       Date:  2019-11-02       Impact factor: 6.250

5.  Disposal of household pharmaceuticals in insular communities: social attitude, behaviour evaluation and prevention activities.

Authors:  Antonis A Zorpas; Maria Dimitriou; Irene Voukkali
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-25       Impact factor: 4.223

6.  Robust antibacterial activity of functionalized carbon nanotube- levofloxacine conjugate based on in vitro and in vivo studies.

Authors:  Marzieh Hassani; Azar Tahghighi; Mahdi Rohani; Malak Hekmati; Maryam Ahmadian; Hassan Ahmadvand
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

Review 7.  Ethinyl estradiol and other human pharmaceutical estrogens in the aquatic environment: a review of recent risk assessment data.

Authors:  James P Laurenson; Raanan A Bloom; Stephen Page; Nakissa Sadrieh
Journal:  AAPS J       Date:  2014-01-28       Impact factor: 4.009

8.  Diclofenac-induced cytotoxicity in cultured carp leukocytes.

Authors:  M Nemcova; J Pikula; J Zukal; V Seidlova
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

9.  To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).

Authors:  Vidya Nand Rabi Das; Niyamat Ali Siddiqui; Biplab Pal; Chandra Shekhar Lal; Neena Verma; Ashish Kumar; Rakesh Bihari Verma; Dhirendra Kumar; Pradeep Das; Krishna Pandey
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

10.  Evaluation of a Novel Approach for Reducing Emissions of Pharmaceuticals to the Environment.

Authors:  Thomas G Bean; Ed Bergstrom; Jane Thomas-Oates; Amy Wolff; Peter Bartl; Bob Eaton; Alistair B A Boxall
Journal:  Environ Manage       Date:  2016-06-24       Impact factor: 3.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.